New Reference: SubQ Rituximab for Follicular Lymphoma

  • Study

    Randomized, open-label phase 3 trial (LYSA)
    Previously untreated low-burden Follicular lymphoma
    SOC (n=102) vs. Rituximab sc (n=100)


  • Efficacy

    cR: 36.3% vs. 59.0%, p=0.001
    4-year PFS: 41.2% vs.58.1%, p=0.008
    4-year OS:95.0 vs.96.7%, p=ns


  • Safety


    Grade3 AEs: Lymphopenia (3.0% in both arm), injection site reaction (3.0% in both arm)



    • J Clin Oncol APR 18, 2023

    Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

    http://doi.org/10.1200/JCO.22.02327

    Reviewed by Elvin Chalabiyev, MD on May 20, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag